Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine

Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects.